PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 3126194-7 1988 Cycloheximide, an inhibitor of protein biosynthesis induced a rapid transient increase of t-PA, u-PA and PAI-1 mRNA and a sustained increase of PAI-2 mRNA, but blocked the more long term effects of Dex, suggesting that both constitutive and hormonally regulated maintenance of mRNA steady state levels required protein biosynthesis. Cycloheximide 0-13 plasminogen activator, urokinase Homo sapiens 96-100 2501786-7 1989 Inhibition of endogenous u-PA production by cycloheximide reduced [3H]thymidine incorporation significantly; after addition of exogenous u-PA, [3H]thymidine incorporation increased again in the cycloheximide-treated cells. Cycloheximide 44-57 plasminogen activator, urokinase Homo sapiens 25-29 2501786-7 1989 Inhibition of endogenous u-PA production by cycloheximide reduced [3H]thymidine incorporation significantly; after addition of exogenous u-PA, [3H]thymidine incorporation increased again in the cycloheximide-treated cells. Cycloheximide 194-207 plasminogen activator, urokinase Homo sapiens 25-29 2501786-7 1989 Inhibition of endogenous u-PA production by cycloheximide reduced [3H]thymidine incorporation significantly; after addition of exogenous u-PA, [3H]thymidine incorporation increased again in the cycloheximide-treated cells. Cycloheximide 194-207 plasminogen activator, urokinase Homo sapiens 137-141 2501387-8 1989 The increase in u-PA message level was augmented in a synergistic fashion by CHX. Cycloheximide 77-80 plasminogen activator, urokinase Homo sapiens 16-20 3102944-4 1987 First, elevation of uPA mRNA after irradiation was severely blocked by cycloheximide. Cycloheximide 71-84 plasminogen activator, urokinase Homo sapiens 20-23 17029796-7 2006 Co-treatment of c-pc with 200 microg/ml cycloheximide (CHX), translation inhibitor, resulted in over accumulation of uPA mRNA. Cycloheximide 40-53 plasminogen activator, urokinase Homo sapiens 117-120 17029796-7 2006 Co-treatment of c-pc with 200 microg/ml cycloheximide (CHX), translation inhibitor, resulted in over accumulation of uPA mRNA. Cycloheximide 55-58 plasminogen activator, urokinase Homo sapiens 117-120 15881651-5 2005 CycD, emitine, puromycin and anisomycin also enhanced uPA mRNA half-life by three- to five-fold in Beas2B cells treated with DRB, an inhibitor of transcription. Cycloheximide 0-4 plasminogen activator, urokinase Homo sapiens 54-57 7548228-3 1995 Northern blot analysis and nuclear run-on assay revealed that uPA gene transcription was repressed by Bt2cAMP and the repression was negated by inhibition of de novo protein synthesis by cycloheximide. Cycloheximide 187-200 plasminogen activator, urokinase Homo sapiens 62-65 11728456-4 2001 uPA effect occurs also in the presence of the transcriptional inhibitor dichloro-ribobenzimidazole, whereas it is abolished by the protein synthesis inhibitor cycloheximide. Cycloheximide 159-172 plasminogen activator, urokinase Homo sapiens 0-3 10709910-6 2000 A protein synthesis inhibitor, cycloheximide, amplified the LPS-induced uPA mRNA, suggesting that LPS induces uPA by activating the gene expression in which de novo protein synthesis is not necessary. Cycloheximide 31-44 plasminogen activator, urokinase Homo sapiens 72-75 10709910-6 2000 A protein synthesis inhibitor, cycloheximide, amplified the LPS-induced uPA mRNA, suggesting that LPS induces uPA by activating the gene expression in which de novo protein synthesis is not necessary. Cycloheximide 31-44 plasminogen activator, urokinase Homo sapiens 110-113 8655604-3 1996 Actinomycin D and cycloheximide inhibited the up-regulation of both uPA and uPA-R, as determined by immunohistochemistry, indicating that RNA and protein syntheses are required for their induction in migrating keratinocytes. Cycloheximide 18-31 plasminogen activator, urokinase Homo sapiens 68-71 8530448-3 1995 Adhesion was found to be inhibited by cycloheximide or actinomycin D, implicating protein synthesis and gene expression in u-PA-induced monocyte adhesion. Cycloheximide 38-51 plasminogen activator, urokinase Homo sapiens 123-127 12117412-4 2002 Recombinant uPA induced the release of MMP9/gelatinase B, as detected by zymography and Western blotting, and this release was abolished by actinomycin D and cycloheximide (inhibitors of DNA transcription and protein synthesis) and partially suppressed by monensin (an inhibitor of secretion). Cycloheximide 158-171 plasminogen activator, urokinase Homo sapiens 12-15 10562909-11 1999 Accumulation of u-PA was inhibited by cycloheximide, implying that there was a requirement for protein synthesis. Cycloheximide 38-51 plasminogen activator, urokinase Homo sapiens 16-20 10361124-3 1999 Upon stimulation with RA, mRNA levels of RARalpha and beta transiently increased in parallel with the induction of uPA, and this increase was inhibited by cycloheximide. Cycloheximide 155-168 plasminogen activator, urokinase Homo sapiens 115-118 1555891-4 1992 Further investigation showed that treatment of BC1 cells with either of the protein synthesis inhibitors, cycloheximide or anisomycin, increased the level of both nuclear and cytoplasmic uPA RNA 6- to 18-fold in 4 hr, whilst inducing a maximum 2.6-fold increase in the rate of uPA gene transcription. Cycloheximide 106-119 plasminogen activator, urokinase Homo sapiens 187-190 7750207-3 1995 The effects of amiloride on the modulation of uPA mRNA and protein induced by phorbol ester (PMA) and cycloheximide (CHX) were studied in four colon cancer cell lines, HCT116, KM12SM, LIM1215 and LS123. Cycloheximide 102-115 plasminogen activator, urokinase Homo sapiens 46-49 7750207-3 1995 The effects of amiloride on the modulation of uPA mRNA and protein induced by phorbol ester (PMA) and cycloheximide (CHX) were studied in four colon cancer cell lines, HCT116, KM12SM, LIM1215 and LS123. Cycloheximide 117-120 plasminogen activator, urokinase Homo sapiens 46-49 1555891-4 1992 Further investigation showed that treatment of BC1 cells with either of the protein synthesis inhibitors, cycloheximide or anisomycin, increased the level of both nuclear and cytoplasmic uPA RNA 6- to 18-fold in 4 hr, whilst inducing a maximum 2.6-fold increase in the rate of uPA gene transcription. Cycloheximide 106-119 plasminogen activator, urokinase Homo sapiens 277-280 1848242-5 1991 The protein synthesis inhibitor cycloheximide (10 micrograms/ml) also increases the level of u-PAR mRNA. Cycloheximide 32-45 plasminogen activator, urokinase Homo sapiens 93-98 1655420-6 1991 The protein synthesis inhibitor cycloheximide also increased the level of u-PAR mRNA in a time-dependent fashion and when both cycloheximide and TGF-beta 1 were used, an additive effect was seen. Cycloheximide 32-45 plasminogen activator, urokinase Homo sapiens 74-79 1655420-6 1991 The protein synthesis inhibitor cycloheximide also increased the level of u-PAR mRNA in a time-dependent fashion and when both cycloheximide and TGF-beta 1 were used, an additive effect was seen. Cycloheximide 127-140 plasminogen activator, urokinase Homo sapiens 74-79 1905804-3 1991 A DNA element, similar to the binding site for the transcription factor NFkB, is located around--1865 with respect to the start site of transcription in the uPA promoter and confers superinducibility by these agents in the presence of cycloheximide (CHX). Cycloheximide 235-248 plasminogen activator, urokinase Homo sapiens 157-160 1905804-3 1991 A DNA element, similar to the binding site for the transcription factor NFkB, is located around--1865 with respect to the start site of transcription in the uPA promoter and confers superinducibility by these agents in the presence of cycloheximide (CHX). Cycloheximide 250-253 plasminogen activator, urokinase Homo sapiens 157-160 1801706-7 1991 The induction of uPA by TNF was inhibited by actinomycin D and cycloheximide implying the necessity of RNA and protein synthesis, respectively. Cycloheximide 63-76 plasminogen activator, urokinase Homo sapiens 17-20 2169831-9 1990 The increase in cell surface uPA produced by exposure to EGF required protein synthesis and could be blocked by cycloheximide. Cycloheximide 112-125 plasminogen activator, urokinase Homo sapiens 29-32